Discover
ELVN
Enliven Therapeutics, Inc.
54.33
1 x 45.80
1 x 55.00
bid
ask
+
0.00
0.00%
1 @ 09:11 AM
53.50 -0.83 (1.53%)
| Ytd | 252.79% | |
| 1y | 148.42% |
day range
14.79
52 week range
54.88
| Open | Prev Close | 54.33 | Low | High | Mkt Cap | 3.88B | |||
| Vol | 0.00 | Avg Vol | 1.30M | EPS | -1.67 | P/E | -32.53 | Forward P/E | -21.97 |
| Beta | 0.24 | Short Ratio | 3.49 | Inst. Own | 90.17% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-13 | 50-d Avg | 44.60 | 200-d Avg | 31.48 | 1yr Est | 66.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-12 | 2026-06 | -0.38 | N/A | N/A | N/A |
| 2026-05-07 | 2026-03 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | -0.42 | -0.48 | -0.06 | -14.29% |
| 2025-11-12 | 2025-09 | -0.43 | -0.32 | 0.11 | 25.58% |
| 2025-08-13 | 2025-06 | -0.53 | -0.49 | 0.04 | 7.55% |
| 2025-05-14 | 2025-03 | -0.51 | -0.57 | -0.06 | -11.76% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Stifel | Upgrade | Buy | Buy |
| 2026-06-29 | Jones Trading | Upgrade | Buy | Buy |
| 2026-06-09 | Stifel | Upgrade | Buy | |
| 2026-06-02 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-05-08 | Goldman Sachs | Upgrade | Buy | Buy |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-07 | BALLAL RAHUL D. | Director | 22.34K | Conversion of Exercise of derivative security |
| 2026-06-16 | COLLINS HELEN LOUISE | Officer | 25.00K | Conversion of Exercise of derivative security |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-06-16 | HOHL BENJAMIN | Chief Financial Officer | 51.00K | Conversion of Exercise of derivative security |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
| 2026-07-05 | KUNKEL LORI ANNE | Director | 41.88K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Orbimed Advisors, LLC | 7.96M | 0.00 | 13.07% |
| 2026-03-30 | FMR Inc | 6.83M | 0.00 | 11.21% |
| 2026-03-30 | Polar Capital Holdings PLC | 5.07M | 0.00 | 8.32% |
| 2026-03-30 | BlackRock Inc | 3.68M | 0.00 | 6.05% |
| 2026-03-30 | COMMODORE CAPITAL LP | 3.28M | 0.00 | 5.38% |
| 2026-03-30 | Vestal Point Capital LP | 3.25M | 0.00 | 5.34% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-04-29 | Polar Capital Healthcare Opports Inc | 2.80M | 0.00 | 4.59% |
| 2026-04-29 | Polar Capital Biotech S Inc | 2.14M | 0.00 | 3.52% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 1.62M | 0.00 | 2.66% |
| 2026-04-29 | Fidelity Select Health Care | 1.15M | 0.00 | 1.89% |
| 2026-03-30 | Fidelity Small Cap Growth | 1.07M | 0.00 | 1.76% |
| 2026-05-28 | iShares Russell 2000 ETF | 943.53K | 0.00 | 1.55% |